The wider role for CFTR potentiators in emerging pharmacological treatments for CF across all classes of CFTR mutations underscores the importance of reconsidering VX-445 as both a corrector and a potentiator, to include this newly-discovered mechanism of action. The gene discussed is CFTR; the disease is cystic fibrosis.